WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 248 participants.
Also called NCT03302494
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 248 participants
- Sponsor
- Registry
-
NCT03302494
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia
- Registry status
- Terminated
Technical summary
Registry record NCT03302494. Randomized; single masking; primary purpose prevention. Start 2017-12-27 (actual); primary completion 2023-12-21 (actual). Results posted on 2025-03-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
- Acronym
- WAVECREST2
- Condition
- Stroke
- Intervention (Device)
- Coherex WaveCrest® Left Atrial Appendage Occlusion System
- Intervention (Device)
- Watchman® LAA Closure Device
- Lead sponsor
- Coherex Medical
- Collaborator
- Biosense Webster, Inc.
Record details
- Record id
cardio:ct-nct03302494- Content hash
deddd04bb4e9000ccc4130a3cb78250c1507ee5732f044a038a4e01f8281698c